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Introduction
Epigenetics literally means “above” the gene and is a new 
study of research in biology that explains how environmental 
factors impact one’s biology. Epigenetic mechanism explains 
how there are over 220 different cell types in an adult organ-
ism even though they all have the same DNA. All cells in each 
organism contains the same DNA, but their cell function dif-
fers in different cells, based on “qualitative and quantitative 
differences in gene expression.” (Gibney, Nolan, 2010). Bone 
cells, skin cells, heart cells, all have the same DNA, but their 
functions are completely different. This cell differentiation is 
a specific pattern of gene expression where certain parts 
of the DNA are turned on or off in each type of cell. This 
specific pattern of gene expression is passed down from 
cell to cell. Epigenetics is defined as “the study of mitotically 
(and potentially meiotically) heritable alterations in gene ex-
pression that are not caused by changes in DNA sequence 
(Gibney, Nolan, 2010). One researcher compares genes and 
epigenetics to a computer, where genes are the hardware and 
epigenetics is the software telling the hardware how to func-
tion. There is a certain balance of epigenetics that is normal 
and healthy for the cell, but when these balances are changed 
and the epigenetic mechanisms become unregulated there 
may be alterations in gene expression, and can ultimately 
lead to cell transformation and malignant outgrowths. There 
are three major types of epigenetic changes; DNA methyl-
ation, Covalent Posttranslational Histone Modification, and 
Small Inhibitory RNA-mediated signaling Pathways. Mainly, 
Epigenetic processes, including DNA methylation and histone 
modification, influence gene expression at the transcription 
level. 
DNA methylation is the most studied epigenetic factor and 
that is what will be discussed in this paper. DNA methyla-
tion occurs through the covalent addition of a methyl group 
(CH3) to the 5 position of a cytosine generating 5-methyl-
cytosine (Stein, Davis, 2012). Methyl groups protrude into 
the major groove of DNA and change the biophysical char-
acteristics of the DNA. Cells can methylate and demethylate 
DNA, which effects specific gene expression. These epigene-
tic changes can experience multigenerational inheritance; not 
only does it change the phenotype of the first individual, but 
the methylation can pass onto further generations.
Materials and Methods
In order to understand how epigenetics can be a potential cure 
for cancer, many journals and articles were retrieved from Touro 
College’s library database.  Those articles and the references 
they listed formed the basis for exploring this topic.
Correlation between DNA methylation and gene 
silencing
An experiment with mice and coat color phenotype and body 
weight measurement exposed the correlation between methyl 
groups and silencing of gene expression. A group of pregnant 
mice that were genetically identical were assembled, half the 
group were fed a diet rich in methyl groups (here soy), and the 
control half their regular diet.  All these mice had the agouti 
gene, which when expressed gives the mouse a yellow color 
and causes obesity. The offspring of the mice that had the methyl 
rich diet were thin and brown, whereas the offspring of the 
mice that did not eat the methyl groups remained yellow and 
fat. They both have the agouti gene, but the brown mice had a 
methyl group attached to the agouti gene which shut it down. 
Bisulfite sequencing methylation analysis of CpG sites in the 
promoter region of the agouti gene (Avy IAP) showed a statisti-
cal increased average percentage of cells methylated of the mice 
given the methyl rich diet.  This was a simple experiment to see 
how DNA methylation affects gene expression because it was 
easy to see when the gene was on and off based on the pheno-
type color switch and body measurement. Also, this epigenetic 
tag was passed down to the offspring’s of these mice, and con-
tinued until they ate a diet without enough methyl groups. Soy 
has an active ingredient that methylates DNA. This research may 
explain why there is a lower incidence of cancer among Asians 
compared to Westerners, because Asians eat diets rich in soy 
and may explain why Asians who emigrate to America are more 
likely to develop cancer than their family back home. (Dolinoy, 
et. al. 2006)
DNA methylation causes gene silencing
Although a correlation was noted between gene activation and 
methylation, the authors wanted to prove conclusively that 
DNA methylation is the cause of the gene silencing. They were 
not positive yet which was the cause and which was the effect, 
they though that it might be possible for the gene inactivation 
to cause the DNA methylation. An experiment was carried 
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out that proved that DNA methylation caused gene inactiva-
tion. The experiment was conducted on the E2a region of Ad2 
DNA. The region was cloned, and then half of the gene was 
methylated in vitro with HpaII DNA methyltransferase and then 
microinjected into the nuclei of X. laevis oocytes. The key is that 
the scientists ensured that the methylated DNA only remained 
methylated for 24 hours after microinjection. There was no syn-
thesis of Ad2 specific RNA in the methylated DNA cells until 24 
hours after injection. The control did however readily express 
the Ad2 specific RNA. The experiment results demonstrate that 
methylation plays an actual role in causing genome inactivation 
because at the end of the 24 hour period, there is no genome 
expression, yet that does not cause the methylation to contin-
ue, which proves that methylation is not a consequence of a 
lack of gene expression. The gene expression inactivation only 
occurred in the narrow window that the Gene was methylated 
(Doerfler, 1981).
How it causes gene silencing
Cytosine methylation inhibits the transcription of genes. When 
there is an extra methyl group on the DNA, it becomes inacces-
sible for protein binding for gene expression.  The methyl group 
interferes with the binding of the protein to its specific DNA 
to transcribe it.
Cancer
Typically, it was believed that cancer was caused by genetic de-
fects such as, mutations, amplifications, deletions and translo-
cations, which affected the cancer cell and provided it with the 
advantage to survive and metastasize. However, today, it is clear 
that there is another system of equal importance that is liable in 
causing cancer, and that is epigenetic marks. Today cancer is con-
sidered a genetic and epigenetic disease. This epigenetic alter-
ations which can cause cancer have been termed epimutations. 
This is extremely important because damage to a cell’s DNA 
is permanent, whereas epigenetic change is reversible. (Stein, 
Davis, 2012).
Proof that epigenetic changes can cause cancer
Take arsenic which is known to cause cancer of the skin, liver, lung, 
and bladder, but actually does not cause DNA mutations, as demon-
strated in standard mutagenic assays. However in 2010, researchers 
found that arsenic caused cancer by epigenetic mechanisms. This 
was a groundbreaking epigenetic mechanism that cause cancer, 
and that is a major breakthrough in terms of finding a cure. One 
group of researchers studied CpG islands of over 14000 genes 
in people who were exposed to high levels of arsenic, verified by 
their urinary arsenic levels. It was found that these genes were 
epigenetically modified from the arsenic exposure, and researchers 
found that a tumor suppressor gene was silenced. This is called 
a “tumor suppresorome,” which is a group of 17 confirmed or 
recognized tumor suppressor genes that are silenced in human 
cancers, most of these through abnormal methylation patterns. 
(Stein, Davis, 2012)
Two ways that DNA Methylation can have an 
impact on carcinogenesis
One is by hypomethylation and one is by hypermethylation. 
Hypomethylation is a decrease in the normal amount of meth-
ylation on DNA. Hypomethylation usually occurs at repetitive 
chromosomal sequences where DNA is normally methylated. 
Researchers found that four out of five cancer patients had 
significant hypomethylation in their cancer cells as compared 
to their neighboring cancer free cells. Hypomethylation, in 
decreasing the normal amount of methylation of the gene, 
decreases the normal amount of gene silencing, i.e. increases 
gene expression. This can result in an activation of genes with 
growth and tumor promoting functions (Lund, Lohuizen, 2004). 
Additionally, hypermethylation, or the increase in the amount 
of DNA methylation can cause a negative impact on the cells, 
and can lead to carcinogenesis. This hypermethylation is found 
at CpG islands, which are most likely found in the 5’ regulatory 
region of the gene, which are not methylated. Here the extra 
methylation causes gene silencing, and tumor suppressor genes 
are being silenced (Feinberg, 2001).  In one experiment, it was 
revealed that the mRNA for RL7NX3, a tumor suppressor gene 
involved in several cancers, is suppressed in primary cutaneous 
melanoma and in metastatic tumors. CpG Island, which are usu-
ally not methylated and transcriptionally active, have been found 
to be abnormally hypermethylated during the development of 
cancer, particularly in tumor suppressor genes. Genes involved 
in cell cycle regulation, DNA repair, (to name two) are very 
epigenetically susceptible (Stein, Davis, 2012).
Hypermethylation of GSTP1 and prostate cancer
Methylation of GSTP1 is the most common epigenetic alteration 
described in several tumors, such as prostate cancer, endometrial 
cancers, and breast cancers. GSTP1 catalyzes the s conjugation 
of GSH, which protects the cell from cytoxic and carcinogenic 
agents. Methylation of GTSP1 gene occurred in 90% of prostate 
cancer tissue from surgical specimens. In this experiment, the 
tissue samples from 144 patients who were having a prostate 
biopsy were examined. Forty two out of the 144 patients were 
diagnosed with prostate cancer. Additionally, there was hyper-
methylation of the GTSP1 gene in 31 out of those 42 patients, 
and only in 2 out of the 102 patients who did not have cancer. 
Since epigenetics is a cause of carcinogenesis, and, therefore, cells 
will exhibit hypermethylation at the onset of the cancer, there is 
potential for using hypermethylation as a biomarker to detect 
the cancer. These genes, and other genes that exhibit hypermeth-
ylation in the early onset of cancer, may eventually be useful as 
a biomarker to detect prostate cancer. However, methylation of 
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the GTSP1 gene may indicate another cancer, and does not indi-
cate prostate cancer, specifically. However there is potential for 
mapping out hypermethylation of other genes and using a multi 
gene profile to improve specificity for cancers. Azacytidine has 
been found to reverse the hypermethylation of the GTSP1 gene, 
and reactivate transcription (Miano et. al. 2007).
Epigenetic tests on identical twins
The best way to study epigenetics is on monozygotic twins 
because they have the same genetic material, but still have dif-
ference in cell expression and their phenotype. There is a high 
discordance rate between identical twins for many diseases, 
even those thought to be genetic. Epigenetic changes through 
environmental variances can be the answer to the phenotypic 
differences of identical twins. Researchers in Madrid studied 80 
identical twins in a range of 3 to 74 years old.  Thirty five per-
cent of the twin pairs had significantly different methylcytosine 
genomic content. Researchers observed that the difference in the 
methylcytosine pattern for the twins increased with the age of 
the twins. The youngest twin pair had their epigenetic pattern 
the most similar, whereas the oldest pair’s epigenetic pattern was 
very different.  Also, they found that twins who had not grown up 
together had the greatest difference of 5’ methyl cytosine levels. 
These differences in methylation of their cells is what causes the 
gene expression and phenotype of monozygotic twins to differ. 
This study indicates that methylation patterns are one reason 
why twins with the same DNA may have different phenotypes. 
Additionally, the fact that the epigenetic differences were more 
distinct in twins who spent less of their lives together indicates 
that major role the environment plays into translating a general 
genotype into different phenotypes detectable.  External factors 
play a great role in gene expression by changing the pattern of 
epigenetic modifications (Fraga, et. al. 2005).
Epigenetics and age correlation
For every cell division there is a potential for epigenetic damage. 
As a person ages, their cells are forced to divide again and again 
to replenish any tissue damage that may have occurred. Each time 
this happens there is a chance for epigenetic damage through an 
altering of the normal methylation pattern of the cell.  Scientists 
can take tissues from an older person and can estimate by looking 
at the epigenetic patterns of the DNA in a particular tissue how 
old the person is, because these epigenetic changes accumulate as 
a person ages. For a cell, aging is counted by how many times the 
cell has divided.  The more damage a cell has, the more times it is 
forced to divide and replenish, and the more chances that there 
is going to be an abnormal pattern of methylation in this cell.  For 
example, smoking and sun exposure can cause skin tissue injury. 
When a person’s skin peels from a sunburn its cells repair that 
damage by dividing and replenishing those cells. In these cases, 
the sun and cigarette exposure can cause actual DNA damage, 
but they also just damage the tissue which leads to cellular repair 
of that injury through cell division, and leads to a gradual accu-
mulation of epigenetic damage. Lungs of heavy smokers can look 
20 times older than nonsmokers. This can explain why there is a 
higher incidence of cancer among older individuals.  With age, the 
amount of exposure he or she has had to environmental toxins 
increases, which can ultimately lead to an abnormal methylation 
pattern (Nova, 2007).
Epigenetic therapy
Epigenetic therapy works to repair the normal methylation pat-
tern of the cell. This is done through DNA methylation inhibition. 
5’Azacytidine and 5-aza-2’-deozycytidine (Decitabine/DAC), the 
two most advanced drugs for epigenetic therapies for cancer. 
Both are in clinical use (Silverman, et. al. 2006). They are DNA 
methyltransferase inhibitors and work by trapping DNA meth-
yl transferases thereby inhibiting methylation, and restoring the 
gene’s normal expression. DNA methyl transferases, known as 
DMTAs, are the enzymes that are responsible for DNA meth-
ylation. DAC incorporates into DNA and forces the methyl 
transferases to form irreversible covalent bonds to DNA. These 
methyl transferases are then targeted for deletion in the prote-
asome. Then, cells divide, without DMTA and there is now DNA 
hypomethylation and reactivation of genes that were silenced 
from the extra methyl groups. However, DAC can also cause cy-
totoxicity when given in high doses, and therefore dosage must 
be monitored.  A positive side to epigenetic therapy of cancer is 
the minimal side effects which is due to the fact that scientist can 
give low doses of the medication with successful results. Whereas 
for cancer drugs scientist have to give the highest dose possible 
of the medication to kill all the harmful cells, epigenetic therapy, 
does not necessitate high doses of the drug because it is not 
aiming to kill all the cells, but rather just to change the abnormal 
methylation patterns of the cancer cells. DAC was not tested 
Table 1 shows a list of that when hypermethylated become 
cancerous. This means that it may be possible to use 
hypermethylation as a biomarker to detect cancer early on.
118
Sara Rivka Margolis
on young children or on pregnant women. The drug does not 
target normal methyl tags for two reasons. Firstly, drugs target 
the area of the most cellular divisions, and in this case, they are 
going to target the cancer cells and leave the normal cells alone. 
Additionally, modification of epigenetic patterns has a large ef-
fect on cancer cells but will hardly have any long term effect on 
the behavior of normal cells. When the drug was stopped the 
normal cells returned to their normal epigenetic pattern, while 
the cancer cells, now healthy cells with normal methylation pat-
terns, did not revert to tumorigenesis. There is potential for all 
other cancers that have an epigenetic origin. Myelodysplastic syn-
drome, also known as MDS, and Acute Myelogenous Leukemia, 
also known as ALS are easier targets for these drugs because the 
cancer cells are in the blood and have easy access to drugs. (Issa, 
2013) These drugs do not work with solid tumors yet. A reason 
that is likely is because it is much harder to incorporate the drugs 
into these cells, which are multiplying much more slowly than 
hematological cancers. Right now, these drugs are being tested 
with solid state tumors and the results have been promising. In 
the laboratory the scientists have been able to adjust the abnor-
mal epigenetic pattern of the solid state tumor with these drugs, 
and are working to mimic these results in the body. The catch is 
that these drugs that prevent methylation can reactivate expres-
sion of multiple silenced genes, even genes that we want silenced, 
like oncogenes, which are genes that have the potential to cause 
cancer. Therefore, the demethylation can be harmful as well as 
helpful. For example, oncogene NT5E is transcriptionally silenced 
by methylation in breast cancer. Therefore hypomethylating that 
area would activate that oncogene and not be helpful. This is why 
in the future it is important to have some sort of epigonomic 
profiling- to identify potentially deleterious silenced genes before 
using epigenetic therapy to pharmacologically reverse resistance 
(Hatzmichael, Crook, 2013).
MDS, AML and other lymphomas
Myelodysplastic syndrome, or MDS, and Acute Myelogenous 
Leukemia, are cancers of the bone marrow.  MDSs are hema-
tological disorders that usually progresses into AML. Years ago, 
patients diagnosed with MDS were basically given a death sen-
tence, there was no cure, and no hope for any remission. It was 
soon realized that MDS was epigenetic in origin. Researchers 
thought to study the epigenetic pattern in patients with MDS 
because of the fact that the patients with the disease have an 
average age of 70. Diseases that target older individuals likely 
have an epigenetic component in it. MDS patients have aberrant 
methylation of their CpG loci and silencing of multiple genes. 
MDS was therefore an ideal candidate for epigenetic therapy, 
and indeed results were positive.  Decitabine was given to over 
100 patients for Acute Myelogenous Leukemia. In fifty percent 
of the patients the disease disappeared fully. Twenty five percent 
achieved some improvements. However, another 25% did not 
respond to the drug, or the drug worked for a short amount of 
time but then stopped working (Nova, 2007).
Conclusion
All in all, the discovery that many cancers have an epigenetic 
origin, has opened a new path for potential cures for cancer. This 
was possible because epigenetic abnormalities are reversible.  It 
is integral to realize that everything one does affects his or her 
health, and the health of future generations. One’s diet and what 
one is exposed to can affect his epigenome and subsequently his 
future generation’s phenotype. We are not just the product of 
our biology, we are also its cause. 
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